[go: up one dir, main page]

ATE251167T1 - Oxazinocarbazole zur behandlung von cns- erkrankungen - Google Patents

Oxazinocarbazole zur behandlung von cns- erkrankungen

Info

Publication number
ATE251167T1
ATE251167T1 AT00948738T AT00948738T ATE251167T1 AT E251167 T1 ATE251167 T1 AT E251167T1 AT 00948738 T AT00948738 T AT 00948738T AT 00948738 T AT00948738 T AT 00948738T AT E251167 T1 ATE251167 T1 AT E251167T1
Authority
AT
Austria
Prior art keywords
oxazinocarbazoles
treatment
cns diseases
cns
diseases
Prior art date
Application number
AT00948738T
Other languages
English (en)
Inventor
Ruth E Tenbrink
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of ATE251167T1 publication Critical patent/ATE251167T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT00948738T 1999-07-28 2000-07-20 Oxazinocarbazole zur behandlung von cns- erkrankungen ATE251167T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14601399P 1999-07-28 1999-07-28
PCT/US2000/019532 WO2001009142A1 (en) 1999-07-28 2000-07-20 Oxazinocarbazoles for the treatment of cns diseases

Publications (1)

Publication Number Publication Date
ATE251167T1 true ATE251167T1 (de) 2003-10-15

Family

ID=22515535

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00948738T ATE251167T1 (de) 1999-07-28 2000-07-20 Oxazinocarbazole zur behandlung von cns- erkrankungen

Country Status (20)

Country Link
US (2) US6448397B1 (de)
EP (1) EP1200447B1 (de)
JP (1) JP2003506328A (de)
KR (1) KR20020015079A (de)
CN (1) CN1165539C (de)
AR (1) AR024963A1 (de)
AT (1) ATE251167T1 (de)
AU (1) AU767282B2 (de)
BR (1) BR0012791A (de)
CA (1) CA2376927A1 (de)
CO (1) CO5031298A1 (de)
DE (1) DE60005685T2 (de)
DK (1) DK1200447T3 (de)
ES (1) ES2208371T3 (de)
MX (1) MXPA02000984A (de)
PE (1) PE20010548A1 (de)
PT (1) PT1200447E (de)
TW (1) TWI222450B (de)
WO (1) WO2001009142A1 (de)
ZA (1) ZA200110539B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100497122B1 (ko) * 2001-08-30 2005-06-29 주식회사 삼양제넥스 페놀옥시다제 시스템을 구성하는 단백질 및 그것의 유전자
SE0103539D0 (sv) * 2001-10-23 2001-10-23 Biovitrum Ab New Use
ATE429916T1 (de) * 2001-11-09 2009-05-15 Biovitrum Ab Publ Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
US6932961B1 (en) 2002-04-16 2005-08-23 Pharmacia & Upjohn Company Oxazinocarbazoles for the treatment of CNS diseases
EP1495031A1 (de) * 2002-04-16 2005-01-12 Pharmacia & Upjohn Company LLC Markierte oxazinocarbazole als diagnostikmittel
ES2291722T3 (es) * 2002-12-03 2008-03-01 Hoffmann La Roche Aminoalcoxiindoles como ligandos 5-ht6-receptores para el tratamiento de transtornos del snc.
BRPI0709817A2 (pt) 2006-04-12 2011-07-26 Wyeth Corp composto da fàrmula i; mÉtodo para o tratamento de um distérbio do sistema nervoso central relacionado ou afetado pelo receptor de 5-ht6 em um paciente que necessita deste; composiÇço farmacÊutica; e processo para a preparaÇço de um composto da fàrmula i

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059491T3 (es) 1987-06-29 1994-11-16 Duphar Int Res Derivados de indol con anillos condensados.
GB8812636D0 (en) * 1988-05-27 1988-06-29 Glaxo Group Ltd Chemical compounds
EP0377238A1 (de) 1988-12-22 1990-07-11 Duphar International Research B.V Annelierte Indolo(3,2-c)-lactame
CA2174543A1 (en) * 1993-10-20 1995-04-27 Nobuyuki Yasuda Indole derivative
WO1997045427A1 (fr) 1996-05-31 1997-12-04 Mochida Pharmaceutical Co., Ltd. DERIVES DE PYRIDOCARBAZOLE AYANT UN EFFET INHIBITEUR DE cGMP-PDE

Also Published As

Publication number Publication date
KR20020015079A (ko) 2002-02-27
DK1200447T3 (da) 2004-02-02
CN1165539C (zh) 2004-09-08
TWI222450B (en) 2004-10-21
EP1200447B1 (de) 2003-10-01
AU6219700A (en) 2001-02-19
CO5031298A1 (es) 2001-04-27
US6821970B2 (en) 2004-11-23
JP2003506328A (ja) 2003-02-18
ZA200110539B (en) 2003-03-24
MXPA02000984A (es) 2002-07-30
US20020169317A1 (en) 2002-11-14
EP1200447A1 (de) 2002-05-02
PE20010548A1 (es) 2001-05-13
BR0012791A (pt) 2002-06-18
AU767282B2 (en) 2003-11-06
AR024963A1 (es) 2002-10-30
US6448397B1 (en) 2002-09-10
CA2376927A1 (en) 2001-02-08
DE60005685T2 (de) 2004-08-12
ES2208371T3 (es) 2004-06-16
WO2001009142A1 (en) 2001-02-08
CN1361781A (zh) 2002-07-31
DE60005685D1 (de) 2003-11-06
PT1200447E (pt) 2004-02-27

Similar Documents

Publication Publication Date Title
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE69903543D1 (de) Formulierungen zur behandlung von magen-speiseröhren reflux
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
ATE384522T1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE60035326D1 (de) Verfahren zur Behandlung von Abwasser
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus
DE60006412D1 (de) Oxazinochinolone zur behandlung von viralen infektionen
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
DE60005685D1 (de) Oxazinocarbazole zur behandlung von cns-erkrankungen
DE60017174D1 (de) Rivastigmine zur behandlung von augenerkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1200447

Country of ref document: EP

REN Ceased due to non-payment of the annual fee